Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: J Community Health. 2014 Oct;39(5):922–934. doi: 10.1007/s10900-014-9932-9

Table 4:

Multivariate Logistic Regression Analysis of HCV Screening and Selection of Point-of-Care HCV Testing among Clients on a Mobile Medical Clinic in New Haven, Connecticut, 2012-2013 (N=1345).

Outcome: Decision to Accept HCV Ab Screening

N=1345
Outcome: Choosing Point-of-Care HCV Ab Screen versus Standard Phlebotomy
N=438
Covariate AOR (95% CI) Marginal Effects (dy/dx) p-value Covariate AOR (95% CI) Marginal Effects (dy/dx) p-value
Prior STI 5.03 (1.76,14.26) 0.36 <0.01 > 15 sex partners 5.84 (3.14, 10.8) 0.41 <0.01
Non-Hispanic White 0.55 (0.36,0.78) −0.11 <0.01 Non-Hispanic White 3.21 (1.58, 5.96) 0.27 <0.01
Non-Hispanic Black 0.76 (0.53, 1.09) −0.05 0.13 Non-Hispanic Black 1.15 (0.62, 1.85) 0.04 0.65
Hispanic Referent Hispanic Referent
US-born 1.76 (1.25,2.46) 0.12 <0.01 US-born 2.31 (1.26, 3.68) 0.21 <0.01
Injection
Drug Use (PWID)
2.21 (1.12,4.46) 0.14 0.03 Injection Drug Use
(PWID)
0.31 (0.19, 1.01) −0.20 0.01
Baby Boomer 0.67 (0.46,0.97) −0.07 0.04
Prior HCV Diagnosis 1.94 (0.94,4.31) 0.16 0.09 Prior HCV Diagnosis 2.10 (0.67, 6.58) 0.18 0.2
Non-injection Drug Use 0.71 (0.82,1.97) 0.05 0.23
Unstable 0.76 (0.50,1.19) −0.04 0.21
Housing
Median AIC: 1392 Median AIC: 67

LEGEND: HCV: Hepatitis C Virus; HCV Ab: Hepatitis C Antibody; STI: Sexually Transmitted Infection; AOR: Adjusted Odds Ratio; CI: Confidence Interval; PWID: People Who Inject Drugs; AIC: Akaike Information Criterion; Covariates significant at the p<0.05 level are boldfaced.